Status:
UNKNOWN
Prediction of the Efficacy of ctDNA in Immunotherapy for Advanced Gastric Cancer
Lead Sponsor:
Sun Yat-sen University
Conditions:
Stomach Neoplasms
Eligibility:
All Genders
18-80 years
Brief Summary
Gastric cancer is one of the common malignant tumors in China, with relatively high incident rate and mortality among the population. Surgery is the conventional treatment option for early and interme...
Detailed Description
Gastric cancer is one of the most common malignant tumors in China, with the second highest incidence and the third highest mortality.Adenocarcinoma accounts for 95% of gastric malignancies and is the...
Eligibility Criteria
Inclusion
- Male or female ≥ 18 years of age at first visit.
- Patients must have histologically confirmed gastric cancer .
- Patients were surgically assessed to be inoperable.
- Patients received second-line or third-line chemotherapy and were treated with immunoassay point inhibitors.
- Patients' early pathological information was complete, including tumor site and pathological type.
- Patients must be able to provide sufficient fresh tissue/biopsies or minimum 5-10 FFPE sections for NGS analysis.
- Patients must be able to follow the study visit schedule and willing to provide peripheral blood samples at the indicated time point.
- Written informed consent must be obtained from patient or patient's legal representative and ability for patient to comply with the requirements of the study.
Exclusion
- Patients who cannot provide peripheral blood samples prior to the surgical treatment will be excluded.
- Patients with severe infection will be excluded.
- Patients with other serious disease besides gastric cancer will be excluded.
- Pregnant women will be excluded.
- Patients who are alcoholic or drug abusers will be excluded.
- Patients with a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data will be excluded.
Key Trial Info
Start Date :
February 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04053725
Start Date
February 1 2019
End Date
November 1 2021
Last Update
September 9 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer center of Sun Yat-sen University
Guangzhou, Guangdong, China, 510060